Novavax (NVAX) Stock Analysis
Novavax (NVAX) trades at $10.34, with a market capitalisation of $1.7B, revenue growth of -61.6% year over year, a net margin of -59.9%. Novavax operates in Biotechnology.
Key figures
| Price | $10.34 |
|---|---|
| Market cap | $1.7B |
| Revenue growth (TTM YoY) | -61.6% |
| Gross margin | 79.2% |
| Net margin | -59.9% |
| Debt to equity | 0.7 |
| Beta | 2.8 |
| 52-week range | $6.20 – $11.97 |
How Skopa analyses NVAX
Skopa writes a separate investment thesis for NVAX through each of five lenses, so the same company can earn different verdicts depending on what you are optimising for: Value weighs what the business is worth against what it costs, Growth asks how fast it can compound from here, Momentum reads price and estimate revisions, Quality tests margin durability and returns on capital, and Contrarian argues where consensus is mispricing it. Each thesis cites the financials it was built from, alongside the risks and catalysts that would change it.